Mainz Biomed B.V. (MYNZ): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYNZ Stock Price Chart Interactive Chart >
MYNZ Price/Volume Stats
| Current price | $11.91 | 52-week high | $30.00 |
| Prev. close | $11.21 | 52-week low | $7.80 |
| Day low | $11.10 | Volume | 19,900 |
| Day high | $12.18 | Avg. volume | 387,656 |
| 50-day MA | $13.64 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | N/A |
Mainz Biomed B.V. (MYNZ) Company Bio
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MYNZ News From Around the Web
Below are the latest news stories about Mainz Biomed Nv that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Mainz Biomed's pre-submission for colorectal cancer test trial accepted by FDAMainz Biomed (NASDAQ:MYNZ) said its pre-submission filed with the U.S. Food & Drug Administration (FDA) for ColoAlert was accepted for review. The FDA will provide feedback to the company on its proposed U.S. clinical trial design for ColoAlert, a detection test for colorectal cancer. The FDA feedback, which is expected in Q2, will provide... |
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlertPivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug AdministrationBERKELEY, Calif. and MAINZ, Germany, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its pre-submission filed with the U.S. Food & Drug Administration (FDA) for ColoAlert has been accepted for review. By accepting the pre-submission for review |
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, MönchengladbachLaboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in EuropeLaboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists, chemists, doctors and other specialists BERKELEY, Calif. and MAINZ, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagn |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory BoardFormer DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, Calif. and MAINZ, Germany, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Rainer Metzger to its Strategic Advisory Board. “We’re thrilled to welcome Rainer who bri |
MYNZ Price Returns
| 1-mo | -12.68% |
| 3-mo | -31.59% |
| 6-mo | 21.53% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 14.63% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...